HLA class II and response to interferon-beta in multiple sclerosis.
To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon-beta (IFN-beta). We analysed the HLA class II genotypes of 96 multiple sclerosis (MS) patients treated with IFN-beta. The patients were classified as responders or non-responders according to clinical criteria: one or more relapses or a sustained increase after 1 year treatment compared with the year prior to IFN-beta therapy of > or = 0.5 points on the Expanded Disability Status Scale (EDSS). There were 66 (69%) responders and 30 (31%) non-responders. Baseline clinical characteristics were similar. We found no association between HLA class II alleles and clinical response to IFN-beta. HLA genotype does not appear to influence the clinical response to IFN-beta in MS patients.